Expanded Indication For Edwards’ Sapien 3 Squarely In Sight
This article was originally published in Clinica
Edwards Lifesciences is on track to earn an expanded indication for its Sapien 3 transcatheter aortic valve replacement (TAVR) system – possibly earlier than expected – as the Sapien 3 observational study shows that patients deemed to be at intermediate risk for surgical complications may have better one-year outcomes with the TAVR system than surgical valve replacement.
You may also be interested in...
A new update from the PARTNER 2A trial shows transcatheter aortic valve replacement with Edwards Lifesciences' Sapien XT yields similar outcomes to valve surgery in intermediate risk patients.
In an interview with Medtech Insight, the lead investigator of SURTAVI, an ongoing trial of Medtronic's CoreValve in intermediate risk patents, says transcatheter aortic valve is continuously improving and will probably soon be indicated for even low-risk patients, but that surgical valve replacement will have an important role to play for the foreseeable future.
Many medtech companies reported their sales and earnings for all of 2016, along with projections for 2017, at the end of January or early February. Medtech Insight has examined their reports as well as the comments of the analysts who track these companies to highlight a few that had especially good years, some that had down years, and some lesser-known companies worth watching in the future.